期刊文献+

福辛普利联合丹参酮ⅡA磺酸钠治疗早期糖尿病肾病的临床研究 被引量:1

下载PDF
导出
摘要 目的:探讨福辛普利联合丹参酮ⅡA磺酸钠治疗早期糖尿病肾病(DN)的治疗效果。方法:将62例早期DN患者随机分为福辛普利组(30例)和联合用药组(32例),均口服福辛普利10 mg/d,联合用药组加丹参酮ⅡA磺酸钠注射液50 mg/d,疗程4周。观察治疗前后尿微量白蛋白,血液流变学各项指标及血糖变化情况。结果:2组UAER均较治疗前减少(P<0.05),但联合用药组优于福辛普利组(P<0.05)。联合用药组治疗后血液流变学各项指标均较治疗前降低(P<0.05),两组治疗前后血糖无明显变化(P>0.05)。结论:福辛普利与丹参酮ⅡA磺酸钠联合治疗早期DN,能改善血液流变学,降低CRP,减少尿微量白蛋白排泄,延缓肾损害的进展。
作者 曹含弘
出处 《吉林医学》 CAS 2010年第19期3072-3073,共2页 Jilin Medical Journal
  • 相关文献

参考文献7

  • 1刘志红.糖尿病肾病[J].中华肾脏病杂志,2000,16(2):126-131. 被引量:220
  • 2钱荣立.关于糖尿病新诊断标准与分型的意义[J].临床内科杂志,2000,17(3):133-133. 被引量:161
  • 3秦岭,陈江华.糖尿病肾病治疗新进展[J].国外医学(老年医学分册),2006,27(1):16-19. 被引量:11
  • 4Bhatt DL,Topol EJ.Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease[J].Med Clin North Am,2000,84(1):163.
  • 5Yagi A.Anti-inflammatory constituents,aloesin and aloemannan in Aloe species and effects of tanshinon VI in Salvia milliorrhiza on heart[J].Yakugaku Zasshi,2003,123(7):517.
  • 6国家药典委员会.中华人民共和国药典[M].北京:化学工业出版社,2000.168.
  • 7Stehouwer CD,Gall MA,Twisk JW,et al.Increased urinary albumin excretion,endothelial dysfunction,and chronic low-grade inflammation in type 2 diabetes:progressive,interrelated,and independently associated with risk of death[J].Diabetes,2002,51(4):1157.

二级参考文献21

  • 1Tuttle KR. Linking metablism and immunology: diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol,2005; 16 (6): 1537-1538.
  • 2Katos S, Luyckx VA, Ors M et al. Renin - angiotensin blockade lowers MCP- 1 expression in diabetic rats. Kidney Int, 1999; 56 (3): 1037-1048.
  • 3Li C, Yang CW, Park CW et al. Long- term treatment with ramipril attenuates renal osteopontin expression in diabetic rats. Kidney Int, 2003; 63 (2): 454-463.
  • 4Lee FT, Cao Z, Long DM et al. Interactions between angiotensin II and NF- kappaB - dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol, 2004; 15 (8): 2139-2151.
  • 5Gruden G, Setti G, Hayward A et al. Mechanical stretch induces monocyte chemoattractant activity via an NF- kappaB - dependent monocyte chemoattractant protein- 1 - mediated pathway in human mesangial cells: inhibition by rosiglitazone. J Am Soc Nephrol, 2005; 16 (3): 688-696.
  • 6Pistrosch F, Herbrig K, Kindel B et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes, 2005; 54 (7): 2206-2211.
  • 7Ota T, Takamura T, Ando H et al. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia, 2003; 46 (6): 843-851.
  • 8Endo K, Miyashita Y, Sasaki H et al. Probucol delays progression of diabetic nephropathy. Diabetes Res Clin Pract, 2005,[Epub ahead of print].
  • 9Bullo B, Zdrojewski Z, Rurkowski Bet al. Mycophenolate mofetil (MMF) therapeutic approach in patients with chronic glomerulonephritis (GN). Kidney Int, 2003; 64 (3): 1139-1141.
  • 10Hou M, Peng J, Shi Y et al. Mycophenolate mofetil (MMF) for the treatment of steroid - resistant idiopathic thrombocytopenic purpura. Eur J Haematol, 2003; 70 (6) : 353 - 357.

共引文献704

同被引文献16

引证文献1

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部